Progenics Pharmaceuticals, Inc.

Management Team

Expand all

Mark R. Baker
Chief Executive Officer: Mr. Baker joined Progenics in 2005 as senior vice president and general counsel and secretary, and has since served as executive vice president, president, and was appointed to the board of directors. Mr. Baker began his career in 1979 as a corporate lawyer with the law firm Dewey Ballantine in New York, where he was a partner and co-chairman of the capital markets group, among other positions, until 1997. From 1997 to 2001, he served ContiGroup Companies, Inc. (formerly Continental Grain Company), a privately held international agri-business and financial concern, as executive vice president, chief legal officer and secretary. Mr. Baker was chief business officer, secretary and a director of New York Water Taxi, a privately held passenger ferry operation, from 2003 to 2005. He holds an A.B. degree from Columbia College and a J.D. from the Columbia University School of Law.
Paul J. Maddon M.D., Ph.D.
Chief Science Officer and Founder: Dr. Maddon is Progenics' founder and has served in various capacities including chairman of the board, chief executive officer, president and chief science officer. A molecular virologist and immunologist by training, he has made seminal contributions to understanding viral entry and infection. Dr. Maddon serves as chair of the advisory committee of The Rockefeller University's Science Outreach Program and is a member of Rockefeller's University Council and the Bridges to Better Medicine Committee. Dr. Maddon serves as a trustee of Columbia University and is a member of the advisory committee of Columbia's Science Honors Program. At Columbia, Dr. Maddon was graduated summa cum laude with a B.A. in biochemistry and was elected to Phi Beta Kappa. He received an M.D. from Columbia's College of Physicians and Surgeons and a Ph.D. in biochemistry and molecular biophysics from its Graduate School of Arts and Sciences.
Robert A. McKinney CPA
Senior Vice President, Finance and Operations & Chief Financial Officer and Treasurer: Robert A. McKinney, C.P.A. became our Chief Financial Officer on March 10, 2005. Mr. McKinney has served as our Vice President, Finance and Operations and Treasurer from January 1993 and became our Senior Vice President, Finance and Operations in February 2006. Mr. McKinney joined us in 1992 as Director, Finance and Operations and Treasurer. From 1991 to 1992, he was Corporate Controller at VIMRx Pharmaceuticals, Inc., a biotechnology research company. From 1990 to 1992, Mr. McKinney was Manager, General Accounting at Micrognosis, Inc., a software integration company. From 1985 to 1990, he was an audit supervisor at Coopers & Lybrand LLP, an international accounting firm. Mr. McKinney studied finance at the University of Michigan, received a B.B.A. in accounting from Western Connecticut State University, and is a Certified Public Accountant.
Robert J. Israel M.D.
Senior Vice President, Medical Affairs: Robert J. Israel, M.D. joined us as Vice President, Medical Affairs in October 1994 and was promoted to Senior Vice President, Medical Affairs in 2002. From 1991 to 1994, Dr. Israel was Director, Clinical Research-Oncology and Immunohematology at Sandoz Pharmaceuticals Corporation. From 1988 to 1991, he was Associate Director, Oncology Clinical Research at Schering-Plough Corporation. Dr. Israel is a licensed physician and is board certified in both internal medicine and medical oncology. He received a B.A. in physics from Rutgers University and an M.D. from the University of Pennsylvania and completed an oncology fellowship at Sloan-Kettering. Dr. Israel has been a consultant to the Solid Tumor Service at Sloan-Kettering.
William C. Olson Ph.D.
Senior Vice President, Research and Development: William C. Olson, Ph.D. joined us in May 1994 serving in various roles of increasing responsibility through his promotion to Vice President, Research and Development in January 2001. From 1989 to 1992, Dr. Olson served as a Research Scientist at Johnson & Johnson, and from 1992 until 1994 he was a Development Scientist at MicroGeneSys, Inc., a biotechnology company. Dr. Olson received a Ph.D. from the Massachusetts Institute of Technology and a B.S. from the University of North Dakota. Both degrees were awarded in the field of chemical engineering.
Benedict Osorio M.B.A.
Senior Vice President, Quality: Benedict Osorio, M.B.A. joined us in July 2005 as Vice President, Quality. He has over 26 years of experience in pharmaceutical quality control and quality assurance. Prior to joining Progenics, Mr. Osorio served as Senior Director, GMP (Good Manufacturing Practices) Compliance at Forest Laboratories from 2001 to 2005. From 1984 to 2001, Mr. Osorio held positions of increasing responsibility with The PF Laboratories (a subsidiary of Purdue Pharma), most recently as Executive Director, Quality Assurance. From 1979 to 1984, he was an analytical chemist with Berlex Laboratories. He earned both an MBA and a Masters of Science in Chemistry from Seton Hall University and a Bachelor of Science in Forensic Science from John Jay College of Criminal Justice.
Nitya G. Ray Ph.D.
Senior Vice President, Manufacturing: Nitya G. Ray, Ph.D. joined us in February 2001 as Senior Director, Manufacturing and was promoted to Vice President, Manufacturing in March 2004. Prior to joining Progenics, Dr. Ray served as Director of Bioprocess Development at Ortec International from 1997 to 2001. From 1993 to 1997, Dr. Ray held positions of increasing responsibility at Hoffmann-La Roche in the areas of GMP Manufacturing and Process Development, and most recently as Research Leader, Biopharmaceuticals. From 1985 to 1993, he held positions of increasing responsibility at Verax Corporation where he developed process technology for biopharmaceutical manufacturing. Dr. Ray received a M.S. and Ph.D. in Chemical & Biochemical Engineering from Rutgers University and a B.S. in Chemical Engineering from Jadavpur University, India.
Ann Marie Assumma M.S.
Vice President, Regulatory Affairs: Ann Marie Assumma, M.S., has served as Vice President, Regulatory Affairs since July 2008. Ms. Assumma joined us in August 2004 as Senior Director, Regulatory Affairs - Biologics and was later promoted to Executive Director, Regulatory Affairs. Ms. Assumma has over 30 years of experience in the pharmaceutical industry and regulatory affairs. Prior to joining Progenics, Ms. Assumma held positions of increasing responsibility in regulatory affairs and compliance in companies including Dov Pharmaceuticals, Emisphere Technologies, Bayer and American Cyanamid. Ms. Assumma earned her M.S. in Pharmacology from New York Medical College and B.S. in Biology from Fordham University.
Vivien Wong Ph.D.
Vice President, Product Development: Vivien Wong, Ph.D. joined Progenics in September 2007 and currently serves as Vice President, Product Development. Prior to joining Progenics, Dr. Wong was Principal at Theritas Pharmaceutical Consultants from 2004 to 2007. From 1989 to 2004, Dr. Wong held positions of increasing responsibility in preclinical development and pharmacology at Emisphere Technologies, Vivoquest, and Regeneron Pharmaceuticals. She received a B.Sc. in Biology from the Mississippi University for Women, a Ph.D. in Anatomy and Neurobiology from the University of Maryland School of Medicine, and completed a postdoctoral fellowship in Neurology at the Albert Einstein College of Medicine. Dr. Wong currently serves on the International Advisory Board of the Molecular Neuroscience Center of Hong Kong University of Science and Technology.